Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Trace Bartels, BS, Logan Moore, Neda Alrawashdh, PharmD, Abhijeet Kumar, Ivo Abraham, PhD RN, Daniel O. Persky, MD, Ali McBride, PharmD, MS

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-141651

Published: 2020

Journal Articles

Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model

Ali McBride, PharmD, MS, Daniel O. Persky, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141748

Published: 2020

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

Max J. Gordon, MD, Andy Kaempf, MS, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, BS, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MDMPH, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-136808

Published: 2020

Journal Articles

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Daniel O. Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, MB ChB, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S. Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 349.

https://doi.org/10.1182/blood-2019-123871

Published: 2019

Journal Articles

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Logan Moore, Trace Bartels, BS, Daniel O. Persky, MD, Abhijeet Kumar, Ivo Abraham, PhD RN, Lauren Sanders, PharmD, Alicia Ortega, PharmD, Alyssa Henglefelt, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 5353.

https://doi.org/10.1182/blood-2019-132148

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Max J. Gordon, MD, Andy Kaempf, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MD, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4286.

https://doi.org/10.1182/blood-2019-124631

Published: 2019

Journal Articles

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Steven I Park, MD, Christine Burnett, Kristina Dabovic, PharmD, Eric T Williams, PhD, Jack P Higgins, PhD, Daniel O. Persky, MD

Blood (2019) 134 (Supplement_1): 4098.

https://doi.org/10.1182/blood-2019-129243

Published: 2019

Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD

Blood (2019) 134 (Supplement_1): 4089.

https://doi.org/10.1182/blood-2019-125310

Published: 2019

Journal Articles

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Adam S. Kittai, MD, Scott R Best, BS, Bria Thurlow, BSc, Basak Gokcora, Andrzej Stadnik, MPH, BS, Renee MacKinnon, Taylor Hashiguchi Rowland, BS, Daniel O. Persky, MD, Byung Park, PhD, Stephen E Spurgeon, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4295.

https://doi.org/10.1182/blood-2019-123586

Published: 2019

Journal Articles

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Paul M. Barr, Hongli Li, PhD, Richard Burack, MD PhD, Michael LeBlanc, PhD, Sonali M. Smith, MD, Ajay K. Gopal, MD, Justin D. Floyd, DO, Daniel O. Persky, MD, Oliver Press, MD PhD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2016) 128 (22): 614.

https://doi.org/10.1182/blood.V128.22.614.614

Published: 2016

Journal Articles

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Abhijeet Kumar, MD, Jose Guillen-Rodriguez, Jonathan H. Schatz, MD, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, MD, Faiz Anwer, MD, Daruka Mahadevan, MD PhD, Daniel O. Persky, MD, Soham D. Puvvada, MD

Blood (2016) 128 (22): 1790.

https://doi.org/10.1182/blood.V128.22.1790.1790

Published: 2016

Journal Articles

A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

Daniel O. Persky, MD, Hongli Li, PhD, Lisa M. Rimsza, MD, Paul M. Barr, MD, Leslie L. Popplewell, MD, Charles L. Bane, MD, Ann Von Gehr, MD, Michael Leblanc, PhD, Richard I. Fisher, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 3931.

https://doi.org/10.1182/blood.V126.23.3931.3931

Published: 2015

Journal Articles

Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis

Reem Diri, PharmD, Ali McBride, PharmD,MS, Christopher Lee, PhD, Alaa Bagalagel, PharmD, Hussain Bakhsh, PharmD, Daniel O. Persky, MD, Karen MacDonald, PhD, Jennifer Martin, MA, Ivo Abraham, PhD

Blood (2015) 126 (23): 4764.

https://doi.org/10.1182/blood.V126.23.4764.4764

Published: 2015

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1

Lingxiao Li, PhD, Praechompoo Pongtornpipat, BS, Timothy Tiutan, BS, BA, Samantha L. Kendrick, PhD, Soyoung Park, MD, Daniel O Persky, MD, Lisa M. Rimsza, MD, Soham D. Puvvada, MD, Jonathan H. Schatz, MD

Blood (2014) 124 (21): 506.

https://doi.org/10.1182/blood.V124.21.506.506

Published: 2014

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Soham D. Puvvada, MD, Daniel O. Persky, MD, Lora Inclan, Jonathan H. Schatz, MD, Ellen M Chase, Jose Guillen, D Roe, Thomas P. Miller, MD

Blood (2013) 122 (21): 4404.

https://doi.org/10.1182/blood.V122.21.4404.4404

Published: 2013

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

Daruka Mahadevan, MD, PhD, Laurence Cooke, BA, Amy Stejskal, MA, Ann Manziello, BS, Carla Morales, Daniel O. Persky, MD, Richard I Fisher, MD, Thomas P. Miller, MD, Wenqing Qi, PhD

Blood (2011) 118 (21): 2721.

https://doi.org/10.1182/blood.V118.21.2721.2721

Published: 2011

Journal Articles

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Jonathan Friedberg, MD, Daruka Mahadevan, MD, PhD, JungAh Jung, PhD, Daniel O. Persky, MD, Izidore S Lossos, MD, Hadi Danaee, SD, Xiaofei Zhou, PhD, E Jane Leonard, Steven H. Bernstein

Blood (2011) 118 (21): 95.

https://doi.org/10.1182/blood.V118.21.95.95

Published: 2011

NARROW

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only